Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02852928 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

European Management Platform for Childhood Interstitial Lung Diseases - chILD-EU Register and Biobank

Study acronym: chILD-EU
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Dec 2024 to Dec 2028v5 Show 4 more changesShow less
    • Study sites: 5 to 3
    • Study completion date: Dec 2025 to Dec 2029
    • Secondary endpoints: details revised at 1 of 1 entry
    • Publications: details revised at 1 of 2 entries
  2. Re-verified, no change to tracked fieldsv4
  3. Study completion date: Dec 2025
    • Start date: Jan 2014 to Dec 2013
    v3
  4. Primary endpoints: 2 to 1
    • Site contacts updated at 1 of 5 sites
    • Secondary endpoints expanded, about 1 word
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Generation of a common European database and biobank Continous assessment and implementation of guidelines and treatment protocols Establishment of a large observational cohort of chILD patients Determination the value of outcomes used in child Assess treatment variations used, deliver data from defined protocols and linked outcomes
Trial Details
NCT Number NCT02852928
Lead Sponsor Matthias Griese
Conditions
(from sponsor)		 Lung Diseases, Interstitial, Pulmonary Alveolar Proteinosis, Pulmonary Eosinophilia, Pulmonary Fibrosis, Respiratory Distress Syndrome, Newborn, Child
Related terms Lung Diseases, Interstitial, Pulmonary Alveolar Proteinosis, Pulmonary Eosinophilia, Pulmonary Fibrosis, Respiratory Distress Syndrome, Newborn
Enrollment 1,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov